HEIDEN WILLIAM K 4

What Happened

• William K. Heiden, a director of Atara Biotherapeutics (ATRA), was granted 12,000 restricted stock units (RSUs) on June 9, 2026. The Form 4 reports an acquisition price of $0.00, so the grant had no out-of-pocket cost to the insider at issuance. This is an award/compensation grant (code A), not a purchase or sale of already outstanding shares.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (filed within the typical two-business-day reporting window).
• Grant size and price: 12,000 RSUs at $0.00 (total reported acquisition value $0).
• Vesting: These RSUs vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to continued service (footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Transaction type/code: Award/Grant (A). No 10b5-1 plan, tax-withholding, or sale indicated.

Context

• RSUs are compensation awards that convert into shares only after vesting; they do not represent immediately tradable shares. Such grants are common for board members and reflect compensation rather than an open-market trading signal. This filing is informational and does not, by itself, indicate the insider’s market view.